Clinical Trial Search

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 13 or Early Discontinuation — 83.5; 85.7; 6.9; -3.1 units on a scale…

Primary: Onset of Psychosis — 10; 14 percentage of sample converting

Primary: Loss of Effect Over Time — 7; 15; 6; 3 Participants

Primary: Positive and Negative Symptom Improvement — 41.3; 40.3; 36.6; 37.3 score on a scale

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26 — 68.9; 28.1 Units on a scale

Primary: Time to Relapse or an Impending Relapse — 0; 3; 1; 14 relapses

Primary: Number of Participants Demonstrating Improvement in Substance Use — 3; 3 participants

Primary: Number of Participants Who Used Outpatient Mental Health Services — 20; 9 Participants — p=.053

Primary: Changes in Positive Schizophrenia Symptoms — 3.21; 3.30; 3.04; 2.89 units on a scale — p=.30

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -9.7; -17.2 Units on a scale — p=0.001

Primary: Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56 — 89.6; 92.0; -19.3; -19.8 Units on a scale — p=0.935

Primary: Biomarkers — 287.37; 340.83; 492.33; 420.17 pg/mL

Primary: Mean Heinrichs-Carpenter Quality of Life Scale Scores Over Time — 51.25; 55.13; 59.15; 60.08 score on a scale — p=0.0145

Primary: Percentage of Participants Assessed as Very Much Improved or Much Improved Based on Clinical Global Impression-Improvement (CGI-I) Scale - Intent-to-treat (ITT)…

Primary: Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52 — 50.65; 58.71; 5.35; 5.96 units on a scale — p=0.8595

Primary: Change From Baseline in PANSS Total Score at Week 6 — -19.3; -16.9; -19.6 score on a scale — p=0.886

Primary: Error Percentage in Antisaccade Task — 22.6; 29.1 Error Percentage in Antisaccade Task — p=<0.05

Primary: Change in Biomarkers of Treatment Response: Dorsal Caudate (DCA) Gamma Amino Butyric Acid (GABA) Levels — -0.65; .0037 institutional units — p=<0.01

Primary: Emotion Recognition as Measured by the Emotion Recognition-40 at the 6 Week Time Point — 7.25; 6.67; 4.38; 6.17 number of correct responses — p=.61

Primary: Genetic Linkage — 5.2 log (odds ratio) — p=<0.001

Primary: Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8 — 5.85; 7.28; 28.4; 12.1 ng/ml

Primary: QTcB Change — 416.50; 416.41; 418.39; 423.27 ms

Primary: Change From Baseline in Abbreviated Extrapyramidal Symptom Rating Scale (ESRS-A) Scores (Cohorts 1 and 2) at Day 10 — -0.2; -0.3; 0.1; 0.0 Units on a scale

Primary: Change in BOLD Signal in Anterior Cingulate Cortex — -0.0188; 0.0124 BOLD signal change (Mismatch vs. Match)

Primary: Number of Participants With Treatment Response Based on Total PANSS Scale Score — 195 Participants

Primary: Average Over Time of Intensity of Cannabis Use (Used to Evaluate Treatment Efficacy) — 0.02; 4.56 Joints per week — p=.088

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24 — 72.4; -6.9 Units on a scale

Primary: Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) — 6.7; 0.9; 3.9; 5.9 T scores — p=<0.03

Primary: Positive and Negative Syndrome Scale (PANSS) Over Time — 81.3; 84.0; 78.3; 75.3 score on a scale — p=0.08

Primary: Change in Positive and Negative Syndrome Scale (PANSS) Score From the Start to the End of the Double-blind Treatment Phase — 81.0; 81.5; 81.7; 79.7 score on a scale